Concepedia

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Giorgio V. Scagliotti, Rabab Gaafar, Anna K. Nowak, Takashi Nakano, Jan P. van Meerbeeck, Sanjay Popat, Nicholas J. Vogelzang, Federica Grosso, Rasha Aboelhassan, Marko Jakopović,

The Lancet Respiratory Medicine · 2019 · 167 citations · 22 references

DOI

Concepts

References

22

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3.1K citations

, , +13

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

Frank Hilberg, Gerald J. Roth, Martin Krššák et al. · Cancer Research · 2008 · 1.1K citations · Full text

, , +17

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015 · 972 citations

, , +10

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck, R. Kaiser, Anders Mellemgaard et al. · The Lancet Oncology · 2014 · 948 citations · Full text

, , +11

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

Michael Byrne, Anna K. Nowak · Annals of Oncology · 2004 · 646 citations · Full text

, , +9